Blog
RSS Feed- All categories
- Australia (TGA)
-
All tags
- Accelerated approval
- Accelerated review
- Advertising
- Affordability
- Application
- Asthma
- Australia
- Biomedical research
- Biosimilar
- Blood product
- Brexit
- Budget
- Business plan
- Canada
- Cancer
- Cardiovascular disease
- Cellular therapy
- Clinical trial
- Collaboration
- Combination product
- Comparison
- Consultation
- Costs
- COVID-19
- Data
- Database
- Decision making
- Development
- Device
- Diagnostic agent
- Digital health
- Dossier
- Drug development
- Drug resistance
- Drug utilisation
- England
- Europe
- Fast track
- Fees and charges
- Funding
- Gene therapy
- Generic medicine
- Geriatrics
- Guidelines
- Health care system
- Health policy
- Health technology assessment
- Hepatitis C
- HIV infection
- Influenza
- Information
- Innovation
- Intellectual property
- Investment
- Labelling
- Listing
- Management
- Market access
- Medicare
- Medicine
- Merger & acquisition
- Multiple sclerosis
- New Zealand
- Nomenclature
- Orphan drug
- Outcome
- Over the counter
- Paediatrics
- Patent protection
- Patient
- Patient reported outcome
- Performance indicators
- Pharmaceutical industry
- Pharmacy
- Pilot
- Placebo
- Post-market review
- Pricing
- Priority review
- Process
- Proposal
- Public health
- Publication
- Randomisation
- Real world evidence
- Regenerative medicine
- Registration
- Regulation
- Report
- Research
- Review
- Risk management
- Russia
- Safety
- Scientific advice
- Singapore
- Social media
- Software
- Standards
- Statistics
- Submission
- Supply
- Surgery
- Survey
- Switzerland
- Symposium
- Targeted therapy
- Taxation
- The Netherlands
- Timelines
- Transparency
- Type 2 diabetes mellitus
- Update
- US
- Vaccine
- Website
- Withdrawal
- Workshop
Posted by Michael Wonder on 10 Jul 2017
TGA to improve the handling of advertising complaints
10 July 2017 - Australia’s therapeutic goods regulator is implementing new arrangements to simplify and improve the handling of complaints about ...